

Arachis hypogaea L. (Palforzia® ▼) for treating peanut allergy in children and young people

The Pan Mersey Area Prescribing Committee recommends the prescribing of Arachis hypogaea L. (Palforzia® ▼), by specialists only, for treating peanut allergy in children and young people in accordance with NICE TA769.

RED

Palforzia® is an oral immunotherapy, consisting of peanut protein, as a defatted powder of *Arachis hypogaea* L. ⁽¹⁾

[NICE technology appraisal TA769](#) recommends Palforzia® within its marketing authorisation, as an option for treating peanut allergy in children aged 4 to 17. Palforzia® may be continued in patients who turn 18 years of age while on treatment. Palforzia® should be used in conjunction with a peanut-avoidant diet. ⁽¹⁾

Prescribing and monitoring of therapy must be retained by a specialist in the management of allergies.

Palforzia® should be administered under the supervision of a health care professional qualified in the diagnosis and treatment of allergic diseases. Initial dose escalation and the first dose of each new up-dosing level are to be administered in a health care setting prepared to manage potential severe allergic reactions. ⁽²⁾

Efficacy data currently are available for up to 24 months of treatment with Palforzia®. No recommendation can be made about the duration of treatment beyond 24 months. ⁽²⁾

NICE anticipates that the uptake of Palforzia® will be impacted by its contraindications, regimen requirements, self-injection prerequisite, potential issues around taste aversion for children who switch to dietary peanut and the long-term commitment required to maintain peanut tolerance. Uptake of Palforzia® is also expected to be affected by capacity within food allergy clinics. ⁽³⁾

NICE estimates that the cost of implementing NICE TA769 is £6,000 per 100,000 population in 2022/23 rising to £16,000 per 100,000 population in 2023/24, £31,000 per 100,000 population in 2024/25, £45,000 per 100,000 population in 2025/26 and then £57,000 per 100,000 population in 2026/27. ⁽³⁾

References

1. National Institute for Health and Care Excellence. Technology Appraisal 769; [Palforzia for treating peanut allergy in children and young people](#), 02 February 2022. Accessed 11 February 2022.
2. Aimmune Therapeutics UK Limited. Summary of product Characteristics; [PALFORZIA](#), July 2021. Accessed 11 February 2022
3. National Institute for Health and Care Excellence. Resource impact report; [Palforzia for treating peanut allergy in children and young people](#) (TA769), 09 February 2022. Accessed 11 February 2022

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.